Fragment/CJC/Ipamorelin Blend Peptide

Triple-action GH axis research blend combining HGH Fragment 176-191 (direct lipolysis via beta-3 adrenergic pathway), CJC-1295 (sustained GHRH receptor activation for GH elevation), and Ipamorelin (selective ghrelin receptor-mediated GH pulse). The three compounds target different GH-related pathways for comprehensive growth hormone axis research.

The Fragment 176-191 / CJC-1295 / Ipamorelin blend engages three distinct but complementary pathways within the somatotropic axis and adipose lipolysis machinery. Each component has been characterized independently in the literature, and their combination is studied because the mechanisms are non-redundant — one mimics a lipolytic GH fragment, one provides sustained GHRH-receptor activation, and one provides pulsatile ghrelin-receptor (GHS-R1a) activation.

HGH Fragment 176-191 — Lipolytic C-Terminal Domain

HGH Fragment 176-191 is a synthetic analog of the C-terminal region of human growth hormone (residues 176–191). Unlike full-length GH, the fragment does not bind the canonical GH receptor with high affinity and therefore does not appear to drive hepatic IGF-1 output in preclinical models. Instead, research suggests the fragment promotes lipolysis in adipocytes and inhibits lipogenesis, with proposed signaling through β3-adrenergic-like pathways and altered fatty acid oxidation. Ng and colleagues demonstrated the lipolytic and anti-lipogenic activity of this C-terminal fragment in ob/ob mouse models without the hyperglycemic effects associated with intact GH.^[1]

CJC-1295 — Long-Acting GHRH Analog

CJC-1295 is a tetra-substituted analog of growth hormone-releasing hormone (GHRH 1–29) with D-Ala, Gln, Ala, and Leu substitutions that confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage. In the DAC (drug-affinity complex) form, a maleimidopropionic acid linker enables covalent binding to circulating albumin, extending half-life to multiple days. The non-DAC variant (also called Modified GRF 1-29 or CJC-1295 without DAC) retains the protease-resistant substitutions but lacks the albumin-binding moiety, yielding a half-life on the order of 30 minutes. CJC-1295 binds the GHRH receptor (GHRHR), a class B GPCR on anterior pituitary somatotrophs, activating Gαs–adenylyl cyclase–cAMP–PKA signaling and increasing GH transcription and pulsatile secretion.^[2]

Ipamorelin — Selective Ghrelin Receptor Agonist

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) growth hormone secretagogue that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons. GHS-R1a coupling to Gαq–phospholipase C–IP3/DAG–PKC drives calcium-dependent GH release. In rat studies, Raun et al. characterized ipamorelin as releasing GH with potency comparable to GHRP-6 but without the parallel increases in ACTH, cortisol, or prolactin observed with earlier secretagogues — a selectivity profile that makes it a frequent comparator in GH-axis research.^[3]

Why the Three Pathways Are Studied Together

GHRH-receptor activation (CJC-1295) and ghrelin-receptor activation (Ipamorelin) are synergistic in vivo: GHRH amplifies the somatotroph response to ghrelin agonists, and ghrelin agonists suppress somatostatin tone, removing the brake on GHRH-driven pulses. Layering HGH Fragment 176-191 onto this dual GH-secretagogue base adds a peripheral lipolytic signal that is mechanistically independent of pituitary GH output. Researchers studying body composition models often select this triple combination specifically because it dissociates the GH-pulse stimulus (central) from the adipose lipolysis stimulus (peripheral).

This research blend contains three independently characterized peptides. Because the product is a multi-component formulation, no single molecular formula, CAS number, or mass is assigned to the blend as a whole. Each component is supplied at research-grade purity (≥98% HPLC) as a co-lyophilized mixture. The table below summarizes the role and identifying chemistry of each component.

Physical Properties of the Blend

Researchers should treat each component as having its own stability profile. CJC-1295 (without DAC) and Ipamorelin are generally stable under standard lyophilized peptide storage conditions, while HGH Fragment 176-191 contains two cysteine residues forming an intramolecular disulfide bond, which is sensitive to reducing agents, repeated freeze-thaw, and prolonged exposure to neutral-to-alkaline aqueous solution.

The Fragment/CJC/Ipamorelin Blend is supplied as a co-lyophilized powder containing three distinct peptides in a single vial. Because the components share a common lyophilization matrix, reconstitution dissolves all three simultaneously, and aliquots drawn for research use will contain a fixed ratio of each peptide. Careful technique is required to preserve the integrity of each component, particularly the disulfide-free but oxidation-sensitive residues present in Ipamorelin and CJC-1295.

Recommended Reconstitution Protocol

1. Allow the vial to reach room temperature (15-20 minutes after removal from -20°C storage) before opening. Cold vials are prone to condensation, which introduces moisture into the lyophilizate.
2. Select diluent: Bacteriostatic water (0.9% benzyl alcohol) is preferred for research applications requiring multi-day vial use. Sterile water for injection is acceptable for single-session experiments.
3. Calculate target concentration: For a vial containing combined peptide mass of, for example, 10 mg, adding 2 mL of diluent yields 5 mg/mL total peptide. The individual component concentrations follow the blend ratio specified on the certificate of analysis.
4. Inject diluent slowly down the inner wall of the vial — never directly onto the lyophilized cake. Direct impact can denature peptide and create foam.
5. Do not shake or vortex. Gently swirl or roll the vial between the palms until the powder is fully dissolved (typically 30-60 seconds). Mechanical agitation degrades peptide bonds and promotes aggregation.
6. Inspect the solution: A properly reconstituted blend is clear and colorless. Cloudiness, particulates, or persistent foam indicate a handling problem and the vial should be discarded.
7. Label immediately with date of reconstitution and final concentration. Store reconstituted vials at 2-8°C and protect from light.

Compound-Specific Handling Notes

Ipamorelin contains an aromatic tryptophan residue that is susceptible to oxidation and photodegradation. Reconstituted solutions should be protected from direct light by wrapping vials in foil or using amber glassware.

CJC-1295 (especially the DAC form) contains a maleimide group designed for covalent albumin binding; this group is reactive and should not be exposed to thiol-containing reagents or reducing buffers during research handling.

HGH Fragment 176-191 is relatively stable in solution but, like all peptides, is sensitive to repeated freeze-thaw cycles. If long-term storage of reconstituted material is required, aliquot into single-use volumes and freeze at -20°C; avoid more than one thaw per aliquot.

Working pH: All three components are stable in the slightly acidic to neutral pH range (5.0-7.4) typical of bacteriostatic water. Avoid alkaline buffers, which accelerate hydrolysis of the peptide backbone.

This product is sold strictly for in-vitro and laboratory research use. It is not intended for human or veterinary administration, and reconstitution protocols described here are for laboratory handling only.

Lyophilized Blend

The co-lyophilized powder should be stored at -20°C for long-term preservation (12+ months under typical research conditions). Short-term storage at 2–8°C for up to several weeks is acceptable, and brief excursions to ambient temperature during transit do not meaningfully degrade dry peptide material. Keep the vial sealed and protected from light and humidity; desiccant packaging is recommended if vials are opened repeatedly.

Reconstituted Solution

Once reconstituted with bacteriostatic water (0.9% benzyl alcohol) or sterile water, the solution should be stored at 2–8°C and used within 14–21 days for the most stable components (CJC-1295 without DAC, Ipamorelin). HGH Fragment 176-191 in solution is somewhat less stable due to its disulfide bond and is best used within 7–14 days of reconstitution if peak purity is required. Bacteriostatic water is preferred over plain sterile water for any solution that will be drawn from repeatedly, because benzyl alcohol suppresses microbial growth.

Component-Specific Stability Notes

• HGH Fragment 176-191: Contains a Cys7–Cys14 disulfide bridge. Avoid reducing agents (DTT, β-mercaptoethanol), strongly alkaline buffers, and prolonged exposure to dissolved oxygen. Repeated freeze-thaw cycles of the reconstituted solution should be minimized.
• CJC-1295 (without DAC): The DPP-IV-resistant substitutions stabilize the N-terminus, but the peptide still undergoes slow aqueous hydrolysis. Refrigerated storage of the reconstituted solution is essential.
• Ipamorelin: Generally the most stable of the three in solution; the C-terminal amide and unnatural residues (Aib, D-2-Nal, D-Phe) resist enzymatic and chemical degradation.

Handling Best Practice

For experiments requiring extended timelines, researchers commonly aliquot the reconstituted solution into single-use low-binding polypropylene tubes and store aliquots at -20°C, thawing each aliquot only once. This avoids repeated freeze-thaw stress on the disulfide-containing Fragment 176-191 component. Document reconstitution date, diluent, and concentration on the vial, and discard any solution showing visible particulates, cloudiness, or discoloration.